Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
NCT04400266Phase 4Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2020
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of buspirone and melatonin in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Primary endpoint: Hamilton Depression Rating Scale at 6 weeks. Started Aug 2020; status: recruiting.
02
Drugs
buspironemelatonin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04400266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04400266.